-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$14.75485.32% Upside
Black Diamond Therapeutics, Inc. Frequently Asked Questions
-
What analysts cover Black Diamond Therapeutics, Inc.?
Black Diamond Therapeutics, Inc. has been rated by research analysts at Raymond James, Piper Sandler, H.C. Wainwright, Wedbush in the past 90 days.